Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Audiology
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Orthopedics
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 851

C3aR Knock-Out Mice

Inventors: Craig Gerard

Invention Types: Research Tool

Research Areas: Allergy/Respiratory/Pulmonary Disease, Cardiovascular/Cardiology, Degenerative Disease

Keywords: Animal Model (mouse), Drug Discovery, Drug Screening

For More Information Contact:  Khunkhun, Rajinder

 

Invention Description:

The complement system is a biochemical cascade that helps clear pathogens from an organism and it bridges the innate and adaptive immune system. The complement system consists of a number of small proteins found in the blood, normally circulating as inactive zymogens. During complement activation, anaphylatoxins, such as C3a, are released, eventually leading to the destruction of the pathogen by the cell-killing membrane attack complex. Dr. Gerard generated mice deficient in the G protein-coupled receptor for C3a (C3aR) by homologous recombination. These mice were born at the expected mendelian ratios, showed no overt developmental or morphologic abnormalities, and were fertile. Mice carrying the C3aR deletion were protected against the changes in lung physiology in a model of allergic airway disease. Human asthmatics have been shown to develop significant levels of ligand C3a following intrapulmonary deposition of allergen.

Applications:

These results indicate that the C3aR -/- mice produced by Dr. Gerard may be useful to study the role of C3aR and C3a in the pathogenesis of human asthma. Asthma affects over 100 million people worldwide and its prevalence is expected to continue to rise. This mouse model could also be utilized to study other pathological conditions involving the complement system, such as autoimmune, inflammatory and ischemia/reperfusion injury-related diseases.

Competitive Advantages:

C3a on binding to C3aR mediates numerous proinflammatory activities. A better understanding of the role of C3aR should lead to the development of therapeutics strategies that would benefit millions of patients suffering from inflammatory and possibly degenerative diseases. A number of promising complement therapeutics are already in development, some of them targeting C3a or its receptor. The well characterized C3aR deficient mice generated by Dr. Gerard could be therefore be used for drug discovery, for drug screening and for studies of the pathogenesis of complement-related diseases.

Business Opportunity:

Non-Exclusive License

Key Publications: Nature 406: 998-1001, 2000

IPStatus: No Protection